Revance Therapeutics
$15.939876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$15.93
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.68 (-4.09%) Today
$0.00 (0.00%) As of 6:00 PM EST after-hours
Why Robinhood?
You can buy or sell RVNC and other stocks, options, ETFs, and crypto commission-free!
About RVNC
Revance Therapeutics, Inc. Common Stock, also called Revance Therapeutics, is a clinical stage biotechnology company. Read More It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
Employees
170
Headquarters
Newark, California
Founded
1999
Market Cap
908.93M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.27M
High Today
$16.86
Low Today
$15.53
Open Price
$16.81
Volume
2.11M
52 Week High
$24.65
52 Week Low
$9.88
Collections
Analyst Ratings
92%
of 12 ratings
Buy
92%
Hold
8%
Sell
0%
RVNC Earnings
-$1.12
-$0.98
-$0.85
-$0.71
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
—
Actual
Expected Feb 26, After Hours